- Home
- VRCA
as 12-20-2024 4:00pm EST
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WEST CHESTER |
| Market Cap: | 363.1M | IPO Year: | 2018 |
| Target Price: | $6.00 | AVG Volume (30 days): | 749.9K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $11.41 | Next Earning Date: | 11-04-2024 |
| Revenue: | $9,210,000 | Revenue Growth: | 187.45% |
| Revenue Growth (this year): | 54.16% | Revenue Growth (next year): | 99.78% |
Latest Verrica Pharmaceuticals Inc. News
VRCA Breaking Stock News: Dive into VRCA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Verrica Provides Business and Operational Update
GlobeNewswire
13 days ago
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
16 days ago
Verrica Pharmaceuticals' Partner Torii Seeks Japan Approval for Skin Infection Treatment
GlobeNewswire
16 days ago
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
GlobeNewswire
a month ago
Verrica Announces Pricing of $42.0 Million Public Offering
GlobeNewswire
a month ago
Verrica Announces Proposed Public Offering
GlobeNewswire
2 months ago
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
GlobeNewswire
2 months ago
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Compare VRCA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRCA Verrica Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.